ML-9

• UNSPSC Description:

  ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity[3]. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54?μM, respectively[1]. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation[3].

• Target Antigen:

  Myosin

• Type:

  Reference compound

• Related Pathways:

  Cytoskeleton

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ml-9.html

• Purity:

  99.86

• Solubility:

  DMSO : 83.33 mg/mL (ultrasonic)|H2O : ≥ 5 mg/mL

• Smiles:

  O=S(N1CCNCCC1)(C2=C3C=CC=C(Cl)C3=CC=C2)=O.[H]Cl

• Molecular Weight:

  361.29

• References & Citations:

  [1]Ito S, et al. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis.Eur J Pharmacol. 2004 Feb 23;486(3):325-33.|[2]Shaikh S, et al. The STIM1 inhibitor ML9 disrupts basal autophagy in cardiomyocytes by decreasing lysosome content.Toxicol In Vitro. 2018 Apr;48:121-127.|[3]Kondratskyi A1, et al.Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death.Cell Death Dis. 2014 Apr 24;5:e1193.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  105637-50-1